Bryan Garnier - BASILEA PHARMACEUTICA (BSLN.S) BASILEA PHARMACEUTICA: Derazantinib is on track to become best-in-class | BUY | CHF102(+102%)

Report

Bryan Garnier

Victor Floc’h

BASILEA PHARMACEUTICA: Derazantinib is on track to become best-in-class | BUY | CHF102(+102%)

BASILEA PHARMACEUTICA - BUY | CHF102(+102%)
Derazantinib is on track to become best-in-class

Looking more than ever at a pipeline-in-a-product opportunity
Safety is FGFR inhibitor’s main limitation in clinical practice
An accelerated approval in sight
Lisavanbulin is Basilea’s wild card for 2021

19/11/2020 3 EN

Underlying

BASILEA PHARMACEUTICA

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Victor Floc’h

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

BASILEA PHARMACEUTICA (BUY, TP CHF91) | Positive phase III results for Cresemba in Japan

July 26, 2021 July 26, 2021 3 EN

Bryan Garnier

BASILEA (BUY, TP CHF91) | Lisavanbulin’s market opportunity strengthened by new epidemiology data

June 7, 2021 June 7, 2021 1 EN

Avantium: EUR10m unlocked for short-term financial needs

Yesterday, Avantium announced that it has unlocked EUR10m in short-term financing, addressing immediate liquidity needs and providing operational runway as the company pursues longer-term funding solutions. The package comprises instruments that were part of the broader EUR46.3m financing framework

1h / 22m 1h / 22m 1 EN

Cédric Rossi ... (+2)

Cédric Rossi
Clément Genelot

Fashion: No sign of spring in second quarter

As we feared in our February sector update, tariffs took a toll on US consumer sentiment, prompting shoppers to become more cautious on discretionary spending. European optimism ticked up marginally as did spending intentions, leading to soft market trends in May-June. In view of constrained pricin

1h / 45m 1h / 45m 1 EN

Antoine Lebourgeois

Antoine Lebourgeois

Eutelsat: EUR1.35bn raise and step towards becoming a strategic French asset

Eutelsat has announced a EUR1.35bn equity raise, including a EUR716m reserved capital increase at EUR4/share and a EUR634m rights issue, underwritten by the French State, Bharti, CMA CGM, and FSP. The capital raise is not unexpected, given prior rumours and Eutelsat's financing needs. The higher su

June 20, 2025 June 20, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BASILEA PHARMACEUTICA: Derazantinib is on track to become best-in-class | BUY | CHF102(+102%)

Monthly LMI Update Independent Investment Research

BASILEA PHARMACEUTICA (BUY, TP CHF91) | Positive phase III results for Cresemba in Japan

BASILEA (BUY, TP CHF91) | Lisavanbulin’s market opportunity strengthened by new epidemiology data

Avantium: EUR10m unlocked for short-term financial needs

Fashion: No sign of spring in second quarter

Eutelsat: EUR1.35bn raise and step towards becoming a strategic French asset

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe